HRP20010225B1 - Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin - Google Patents

Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin

Info

Publication number
HRP20010225B1
HRP20010225B1 HR20010225A HRP20010225A HRP20010225B1 HR P20010225 B1 HRP20010225 B1 HR P20010225B1 HR 20010225 A HR20010225 A HR 20010225A HR P20010225 A HRP20010225 A HR P20010225A HR P20010225 B1 HRP20010225 B1 HR P20010225B1
Authority
HR
Croatia
Prior art keywords
acetyldinaline
capecitabine
gemcitabine
cisplatin
chemotherapy
Prior art date
Application number
HR20010225A
Inventor
William Richard Grove
Wayne Daniel Klohs
Ronald Lynn Merriman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HRP20010225A2 publication Critical patent/HRP20010225A2/en
Publication of HRP20010225B1 publication Critical patent/HRP20010225B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HR20010225A 1998-09-25 2001-03-23 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin HRP20010225B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25
PCT/US1999/015386 WO2000018393A1 (en) 1998-09-25 1999-07-08 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin

Publications (2)

Publication Number Publication Date
HRP20010225A2 HRP20010225A2 (en) 2002-04-30
HRP20010225B1 true HRP20010225B1 (en) 2004-10-31

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010225A HRP20010225B1 (en) 1998-09-25 2001-03-23 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin

Country Status (34)

Country Link
US (3) US6469058B1 (en)
EP (1) EP1115391B1 (en)
JP (1) JP2002525320A (en)
KR (1) KR20010075348A (en)
CN (1) CN1319009A (en)
AP (1) AP2001002109A0 (en)
AT (1) ATE225655T1 (en)
AU (1) AU762079B2 (en)
BG (1) BG105470A (en)
BR (1) BR9913952A (en)
CA (1) CA2342981A1 (en)
CZ (1) CZ2001905A3 (en)
DE (1) DE69903458T2 (en)
DK (1) DK1115391T3 (en)
EA (1) EA200100369A1 (en)
EE (1) EE200100187A (en)
ES (1) ES2185378T3 (en)
GE (1) GEP20043199B (en)
HK (1) HK1040190A1 (en)
HR (1) HRP20010225B1 (en)
HU (1) HUP0103640A3 (en)
ID (1) ID30046A (en)
IL (1) IL141951A0 (en)
IS (1) IS5888A (en)
NO (1) NO20011493L (en)
NZ (1) NZ510504A (en)
OA (1) OA11659A (en)
PL (1) PL348673A1 (en)
PT (1) PT1115391E (en)
SK (1) SK3602001A3 (en)
TR (1) TR200100859T2 (en)
WO (1) WO2000018393A1 (en)
YU (1) YU22401A (en)
ZA (1) ZA200102233B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL348673A1 (en) * 1998-09-25 2002-06-03 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
CZ20022216A3 (en) * 2001-07-02 2003-05-14 Warner-Lambert Company Compound chemotherapy
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
EP2082737B1 (en) * 2002-03-04 2014-12-31 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
MXPA04010199A (en) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Combination therapy for the treatment of cancer.
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
JP2006508974A (en) * 2002-11-15 2006-03-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Combination chemotherapy comprising MEK inhibitor and capecitabine (CAPECITABINE) for treating cancer
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
PE20050206A1 (en) * 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE
CN100431606C (en) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 Anti-cancer medicine composition
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (en) * 2005-04-05 2008-12-17 吴一心 Combination of sweet-scented osmanthus and plantinum chemotherapeutic medicine
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
CN101268474A (en) * 2005-07-22 2008-09-17 断层放疗公司 Method and system for evaluating delivered dose
CA2616304A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
KR20080039920A (en) 2005-07-22 2008-05-07 토모테라피 인코포레이티드 System and method of evaluating dose delivered by a radiation therapy system
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
US8229068B2 (en) 2005-07-22 2012-07-24 Tomotherapy Incorporated System and method of detecting a breathing phase of a patient receiving radiation therapy
WO2007014108A2 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treament plan
CA2616293A1 (en) 2005-07-23 2007-02-01 Tomotherapy Incorporated Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch
CN101534852B (en) 2006-08-31 2013-02-13 光谱医药公司 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
WO2009096245A1 (en) * 2008-01-28 2009-08-06 Nanocarrier Co., Ltd. Pharmaceutical composition and combined agent
FR2937867B1 (en) * 2008-11-03 2011-03-04 Biorebus PHARMACEUTICAL ASSOCIATION CONTAINING LIPOIC ACID AND HYDROXYCITRIC ACID AS ACTIVE INGREDIENTS.
ES2593088T3 (en) 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivatives of (2'-Deoxy-Ribofuranosil) -1,3,4,7-Tetrahydro- (1,3) Diazepin-2-one for Cancer Treatment
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
US9443633B2 (en) 2013-02-26 2016-09-13 Accuray Incorporated Electromagnetically actuated multi-leaf collimator
US10189797B2 (en) * 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6878198A (en) * 1997-04-24 1998-11-13 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
PL348673A1 (en) * 1998-09-25 2002-06-03 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin

Also Published As

Publication number Publication date
TR200100859T2 (en) 2001-08-21
OA11659A (en) 2004-12-08
HRP20010225A2 (en) 2002-04-30
GEP20043199B (en) 2004-03-25
BG105470A (en) 2001-12-29
EE200100187A (en) 2002-08-15
NO20011493L (en) 2001-05-23
CZ2001905A3 (en) 2001-08-15
CN1319009A (en) 2001-10-24
EA200100369A1 (en) 2001-10-22
ID30046A (en) 2001-11-01
DE69903458D1 (en) 2002-11-14
NO20011493D0 (en) 2001-03-23
PT1115391E (en) 2003-02-28
CA2342981A1 (en) 2000-04-06
WO2000018393A1 (en) 2000-04-06
US20030170300A1 (en) 2003-09-11
KR20010075348A (en) 2001-08-09
ZA200102233B (en) 2002-06-18
AU762079B2 (en) 2003-06-19
US20030086965A1 (en) 2003-05-08
SK3602001A3 (en) 2002-07-02
YU22401A (en) 2004-03-12
BR9913952A (en) 2001-06-12
PL348673A1 (en) 2002-06-03
HUP0103640A2 (en) 2002-06-29
AU5092199A (en) 2000-04-17
EP1115391A1 (en) 2001-07-18
EP1115391B1 (en) 2002-10-09
DE69903458T2 (en) 2003-07-10
ATE225655T1 (en) 2002-10-15
US6469058B1 (en) 2002-10-22
HK1040190A1 (en) 2002-05-31
JP2002525320A (en) 2002-08-13
ES2185378T3 (en) 2003-04-16
IS5888A (en) 2001-03-14
DK1115391T3 (en) 2003-02-10
NZ510504A (en) 2003-09-26
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
AP2001002109A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
HUP0103640A2 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
HK1034978A1 (en) Adenosine derivatives.
EP1137347A4 (en) Multi-component lightweight ballistic resistant garment
EE200000577A (en) Improvements to, or associated with, electronic passageways
ZA992255B (en) Antitumor synergetic composition.
HK1038690A1 (en) Powdery pernasal compositions.
IL143939A0 (en) Combination chemotherapy
EP1073817A4 (en) Slide latch
HK1041482A1 (en) Naphtho-and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents.
SI1115391T1 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
AU137894S (en) Slide latch
ZA991138B (en) Streptomyces avermitilis gene directing the ratio of B2: B1 avermectins.
ZA200000390B (en) Door closer.
ZA991619B (en) Cancer management.
GB9903035D0 (en) Treating cancer
GB2334579B (en) Treating cancer
HK1041989A1 (en) Access channel slot sharing.
IL137605A0 (en) Nucleosides
IL126821A0 (en) Weapon lock
ZA99886B (en) 5'-Deoxycytidine derivatives.
GB9804050D0 (en) Cancer
AU135507S (en) Slide latch
GB9807773D0 (en) Anti-cancer agent
GB9813674D0 (en) Anti-cancer agent
AU2096P (en) SIR DON Prunus avium

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBC Application rejected